Skip to main content
Erschienen in: Medical Oncology 3/2011

01.09.2011 | Original Paper

Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer

verfasst von: Parvin Mehdipour, Marzieh Mahdavi, Javad Mohammadi-Asl, Morteza Atri

Erschienen in: Medical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The involvement of ATM gene and specifically, the important role of D1853N polymorphism, as a three-hit hypothesis has been previously reported in an Iranian proband affected with brain tumor and this polymorphism could be screened in her relatives as well. The aim of present study was to investigate the involvement of D1853N polymorphism as a predisposition factor in 129 Iranian patients affected with primary breast cancer and 248 sex- and age-matched healthy controls. Mutant allele-specific PCR amplification (MASA) assay was performed to analyze the D1853N polymorphism in the ATM gene. The frequency of D1853N polymorphism in cases, internal and external controls was 31.0% (40/129), 26.9% (28/104) and 12.5% (18/144), respectively. The frequency of D1853N in total control groups, including normal external control and pedigree internal control, was 18.6% (46/248). The odds ratio was calculated with the logistic regression test, with an estimated relative risk of 2.579 (P = 0.005). The significant difference was observed between the patient-carriers of this alteration and external controls (P = 0.001). The number of controls harboring D1853N polymorphism was higher in internal control compared to external controls, and the difference was statistically significant (P = 0.004). The significant difference was observed between the patient-carriers and external controls and could be considered as a predisposing and diagnostic marker in the population and specifically in the cancer-prone pedigrees.
Literatur
1.
Zurück zum Zitat Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.PubMedCrossRef Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.PubMedCrossRef
2.
Zurück zum Zitat Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55(14):3003–7.PubMed Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55(14):3003–7.PubMed
3.
Zurück zum Zitat Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosom Cancer. 1999;25(3):212–21.PubMedCrossRef Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosom Cancer. 1999;25(3):212–21.PubMedCrossRef
4.
Zurück zum Zitat Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994;54(17):4586–9.PubMed Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994;54(17):4586–9.PubMed
5.
Zurück zum Zitat Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, et al. Loss of heterozygosity at 11q22–q23 in breast cancer. Cancer Res. 1994;54(23):6270–4.PubMed Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, et al. Loss of heterozygosity at 11q22–q23 in breast cancer. Cancer Res. 1994;54(23):6270–4.PubMed
6.
Zurück zum Zitat Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79.PubMedCrossRef Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79.PubMedCrossRef
7.
Zurück zum Zitat Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3(10):1155–9.PubMedCrossRef Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3(10):1155–9.PubMedCrossRef
8.
Zurück zum Zitat Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17(1):96–9.PubMedCrossRef Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17(1):96–9.PubMedCrossRef
9.
Zurück zum Zitat Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91(10):3920–6.PubMed Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91(10):3920–6.PubMed
10.
Zurück zum Zitat Yuille MA, Coignet LJ, Abraham SM, Yaqub F, Luo L, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16(6):789–96.PubMedCrossRef Yuille MA, Coignet LJ, Abraham SM, Yaqub F, Luo L, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16(6):789–96.PubMedCrossRef
11.
Zurück zum Zitat Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820–3.PubMedCrossRef Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820–3.PubMedCrossRef
12.
Zurück zum Zitat Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef
13.
Zurück zum Zitat Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat. 1997;10(2):100–7.PubMedCrossRef Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat. 1997;10(2):100–7.PubMedCrossRef
14.
Zurück zum Zitat Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92(2):130–4.PubMedCrossRef Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92(2):130–4.PubMedCrossRef
15.
Zurück zum Zitat Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134(11):1173–80.PubMedCrossRef Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134(11):1173–80.PubMedCrossRef
16.
Zurück zum Zitat Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000;66(2):494–500.PubMedCrossRef Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000;66(2):494–500.PubMedCrossRef
17.
Zurück zum Zitat FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307–10.PubMedCrossRef FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307–10.PubMedCrossRef
18.
Zurück zum Zitat Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosom Cancer. 1999;26(4):286–94.PubMedCrossRef Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosom Cancer. 1999;26(4):286–94.PubMedCrossRef
19.
20.
Zurück zum Zitat Kheirollahi M, Mehrazin M, Kamalian N, Mehdipour P. Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors. Med Oncol. 2010. doi:10.1007/s12032-009-9412-8. Kheirollahi M, Mehrazin M, Kamalian N, Mehdipour P. Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors. Med Oncol. 2010. doi:10.​1007/​s12032-009-9412-8.
Metadaten
Titel
Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer
verfasst von
Parvin Mehdipour
Marzieh Mahdavi
Javad Mohammadi-Asl
Morteza Atri
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9525-0

Weitere Artikel der Ausgabe 3/2011

Medical Oncology 3/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.